复星医药：2025年前三季度归属于上市公司股东的净利润同比增长25.50%

Core Insights - Fosun Pharma reported a revenue of 29,393,385,360.91 yuan for the first three quarters of 2025, representing a year-on-year decline of 4.91% [1] - The net profit attributable to shareholders of the listed company was 2,523,293,508.22 yuan, showing a year-on-year increase of 25.50% [1] Financial Performance - Revenue for the first three quarters of 2025: 29.39 billion yuan, down 4.91% year-on-year [1] - Net profit for the same period: 2.52 billion yuan, up 25.50% year-on-year [1]